Table 2. Subgroup analysis according to monotherapy control arm (chemotherapy or immunotherapy) and class of immune checkpoint inhibitor (anti-CTLA-4 mAb or anti-PD-1/PD-L1 mAb).

Subgroup analysis by control arm in monotherapy	Chemotherapy in monotherapy	Immunotherapy in monotherapy	p-value for difference
All grade-AEs	RR 1.03; 95% CI 0.99–1.07	RR 1.13; 95% CI 1.00–1.28	0.15
Grade 3/4 AEs	RR 1.30; 95% CI 1.09–1.54	RR 1.54; 95% CI 1.00–2.36	0.48
Deaths	RR 1.32; 95% CI 0.85–2.05	RR 0.87; 95% CI 0.10–7.89	0.72
Discontinuations	RR 2.40; 95% CI 1.24–4.65	RR 1.51; 95% CI 0.67–3.42	0.39

Subgroup analysis by class of immune checkpoint inhibitor	anti-CTLA-4 mAb	anti-PD-1/PD-L1 mAb	p-value for difference
All grade-AEs	RR 1.06; 95% CI 1.03–1.10	RR 1.00; 95% CI 0.99–1.02	0.0004
Grade 3/4 AEs	RR 1.42; 95% CI 1.14–1.79	RR 1.11; 95% CI 0.96–1.28	0.07
Deaths	RR 1.92; 95% CI 0.83–4.45	RR 1.11; 95% CI 0.67–1.86	0.28
Discontinuations	RR 3.22; 95% CI 1.66–6.23	RR 1.34; 95% CI 1.07–1.67	0.01